Evaluation of Dengue Virus Anti-NS1 Antibody Responses Following Live Attenuated Tetravalent Vaccination in a Clinical Trial
Dengue is a mosquito-borne viral infection endemic in many of the tropical and sub-tropical regions around the world and lacks commercially available vaccines or dengue virus (DENV)-specific chemotherapeutics. During DENV infection, DENV non-structural protein 1 (NS1) is the only secreted nonstructural protein and can be found in the blood of infected individuals from as early as day 1 of symptom onset, and has been hypothesized to contribute to vascular leak during dengue hemorrhagic fever and dengue shock syndrome. We hypothesize that DENV serotype NS1 specific antibodies may be protective against development of severe disease following heterologous challenge and serve as a correlate of protection during evaluation of clinical vaccine trials. The focus of my project is to evaluate the DENV NS1 serotype cross-reactive between anti-NS1 antibodies following both natural infection and clinical tetravalent vaccine trial.
Message to Sponsor
- Major: Molecular and Cell Biology - Immunology, Public Health, Global Poverty and Practice
- Sponsor: SURF Rose Hills fellow
- Mentor: Eva Harris, Public Health